Kairos Pharma, Ltd. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Kairos Pharma, Ltd. (KAPA) on December 13, 2024, reporting events that occurred on December 10, 2024. The company is an emerging growth company incorporated in Delaware and trades on the NYSE American.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The report focuses exclusively on corporate governance changes.
Material Changes
- Resignation of Director: Dr. Rosemary Mazanet resigned from the Board of Directors effective upon the appointment of her successor. The resignation was due to personal reasons and not due to any disagreement with the Company regarding operations, policies, or practices.
- Appointment of Director: Dr. Rahul Singhvi was appointed to the Board of Directors effective immediately. He will serve on the audit committee and chair the compensation committee and the nominating and corporate governance committee.
Management Commentary and Compensation
Management highlighted Dr. Singhvi's extensive background in the Life Sciences industry, including his roles as former President and CEO of Novavax, Inc., and former COO of Takeda's Vaccine Business Unit. In conjunction with his appointment, the Company entered into a Director Offer Letter with the following compensation terms:
- Cash Fee: $50,000 annual cash fee, payable in equal quarterly installments.
- Equity Grant: $50,000 in restricted stock units (RSUs) under the 2023 Equity Incentive Plan, vesting annually in three substantially equal installments.
The filing states there are no family relationships between Dr. Singhvi and other directors or officers, and no undisclosed arrangements regarding his selection.
Investor Verification Checklist
- Verify the effective date of Dr. Mazanet's resignation relative to the appointment of the new director.
- Review the vesting schedule details for the $50,000 RSU grant to Dr. Singhvi in the attached Exhibit 10.1.
- Confirm Dr. Singhvi's independence status and committee assignments as disclosed.
- Note that this filing contains no financial performance data; refer to the most recent 10-K or 10-Q for financial metrics.